Dr. Peter B. Corr and Jean-Pierre Lehmann Appointed to Cibus Global Board of Directors

SAN DIEGO--(Business Wire)--
Cibus Global, a leading plant trait development company, today announced the
appointment of two board members to reflect its growing international reach.
Peter B. Corr, Ph.D., co-founder and general partner of Celtic Therapeutics
Management and former Corporate Senior Vice President of Science and Technology
at Pfizer, brings to the Cibus Board of Directors three decades of experience in
molecular biology, research and product development. Jean-Pierre Lehmann is an
international businessman who has spent more than 20 years overseeing private
company investments in diversified industries.

"Bringing these two distinguished directors to Cibus Global`s board is another
step toward expanding our footprint internationally," said Stephen Evans-Freke,
Chairman of Cibus Global. "We`re pleased to have Peter and Jean-Pierre`s
expertise in scientific research, international development and financial
strategy to help build Cibus Global into a significant player in global
agri-business."

"Cibus Global`s technology holds the potential to revolutionize product
development programs in many areas," said Dr. Corr. "This is a unique technology
platform that, in my view, will incorporate traits in plants that will increase
the availability of healthy food, feed and fiber, as well as provide a new
source for energy. I am pleased to contribute my experience and knowledge to
this endeavor."

"The recent Mahkteshim-Agan agreement validates that Cibus Global`s
environmentally-friendly technology has now come of age and will make
significant changes to agriculture on a global scale, particularly in the
European Union," said Mr. Lehmann.

Peter B. Corr, Ph.D.

Before founding Celtic Therapeutics in 2007, Dr. Corr headed worldwide
pharmaceutical research and development at Pfizer as senior vice president for
Science and Technology. Previously, Dr. Corr was executive vice president,
Pfizer Global Research & Development; and president, Worldwide Development. He
also served as senior vice president, Discovery Research, at Monsanto/Searle and
then, president of Pharmaceutical Research and Development at Warner
Lambert/Parke Davis.

Dr. Corr also has an extensive academic background, spending two decades as a
professor and researcher at Washington University in St. Louis. His research has
been published in more than 160 scientific manuscripts.

Honors include induction into the Alpha Omega Alpha National Medical Honorary
Society, an Established Investigator Award from the American Heart Association
and a Research Career Development Award from the National Institutes of Health
and Washington University Distinguished Faculty Award. Dr. Corr received his
doctorate from Georgetown University School of Medicine.

Jean-Pierre Lehmann

Jean-Pierre Lehmann has been a private investor for the past 17 years, with a
diversified portfolio in venture capital, as well as hotels and commercial and
residential real estate in the United States. Prior to this, Mr. Lehmann resided
in Geneva, Switzerland, where he managed portfolios for Morval Bank and its
holding company. He previously oversaw a diversified holding company for Edmond
de Rothschild.

Mr. Lehmann is a graduate of the Ecole des Hautes Etudes Commerciales in Paris
and holds an M.B.A. from Harvard Business School; he was also an officer in the
French Navy.

About Cibus Global

Cibus Global (www.cibus.com) develops advantageous crop traits with far-reaching
implications in agriculture, alternative energy and product development. Through
its proprietary Rapid Trait Development System (RTDSTM), Cibus creates traits in
a directed way with more precision than traditional breeding techniques and
without the introduction of foreign genetic material. RTDS has proven itself in
the laboratory with several different applications, as well as in initial field
trials of Cibus` first commercial crop, canola. Cibus` products will be brought
to market through a number of strategic partnerships.

For Cibus Global
Julia Monti, 646-695-7044
julia@rosengrouppr.com

Copyright Business Wire 2009